Vicky B. Gregg, a director at Quest Diagnostics Inc, has reported acquiring 63 shares of the company's common stock. This acquisition, dated October 21, 2026, is significant as it demonstrates her ongoing commitment to the firm.
The move is particularly noteworthy in the context of the medical laboratory services industry, where insider transactions can signal confidence in a company's future performance. Gregg's acquisition comes at a time when the industry is navigating various challenges and opportunities.
Background
Quest Diagnostics Inc, identified by CIK 0001022079, operates within the medical laboratories sector, classified under the Standard Industrial Classification (SIC) code 8071. The company is incorporated in Delaware and has its business address at 500 Plaza Drive, Secaucus, NJ. Quest Diagnostics is known for providing diagnostic testing services and has been a key player in the healthcare industry.
What the Filing Says
According to the recent SEC filing (accession number 0001022079-26-000114), Gregg's transaction was executed at a price of $235.939 per share. Following this acquisition, she now owns a total of 18,449 shares of Quest Diagnostics. The filing notes that the shares were acquired through a dividend reinvestment plan, which allows shareholders to reinvest dividends into additional shares.
Impact
This transaction may affect various stakeholders, including other shareholders, potential investors, and competitors in the medical laboratory sector. Insider purchases, like Gregg's, can influence market perceptions and investor sentiment, especially in a competitive landscape.
What's Next
The filing does not say what happens next.